Figitumumab (** Generic name only (no brand names as development was discontinued) **)
Immunotherapy
Description
Figitumumab was investigated for its potential in colorectal cancer but development was discontinued due to lack of efficacy and adverse events. It was intended to be used as a targeted therapy in combination with other agents, aiming to inhibit IGF-1R signaling which is overexpressed in many cancers.
Mechanism of Action
Figitumumab is a fully human monoclonal antibody that targets the insulin-like growth factor-1 receptor (IGF-1R), inhibiting its activation and downstream signaling pathways, which are involved in cell proliferation and survival.
Side Effects
Fatigue; nausea; diarrhea; vomiting; anemia; neutropenia; thrombocytopenia;
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT00976508
Phase 1
Archived
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
United States, Canada, Finland, Germany